National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 18 of 41
Immune Response to Varicella-Zoster Vaccination and Infection
NCT00921999
Influenza Vaccine in Pregnant Women
NCT00905125
Viral Triggers in Pediatric Lung Transplantation
NCT00891865
A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis
NCT00913692
High Dose IMVAMUNE® in Vaccinia-Naive Individuals
NCT00879762
Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection
NCT00911430
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
NCT00768729
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
NCT00865566
Combination Pain Therapy in HIV Neuropathy
NCT00863057
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
NCT00851786
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
NCT00890162
Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali
NCT00889616
Dose Escalation Study of SQ109 in Healthy Adult Volunteers
NCT00866190
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
NCT00730028
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
NCT00729937
Normal Blood, Bone Marrow and Buccal Mucosa Protocol
NCT00806364
VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...
NCT00858611
Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali
NCT00863408
Malaria Challenge With NF54 Strain
NCT00744133
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
NCT00837434
Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
NCT00695877
Safety of Acidform Lubricant in HIV-Uninfected Women
NCT00850837
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
NCT00801697
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
NCT00822276
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
NCT00839436
Pertussis Vaccine in Healthy Pregnant Women
NCT00707148
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
NCT00820846
Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
NCT00829985
Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine
NCT00920517
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
NCT00396370
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
NCT00712803
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
NCT00801632
Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3
NCT00789880
Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
NCT00776412
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
NCT00574600
H5N1 (Clade 2) Vaccination of Adults and Elderly
NCT00680069
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
NCT00774852
Vitamin D3 in Systemic Lupus Erythematosus
NCT00710021
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT00796705
Vaccine for Prevention of Bird Flu
NCT00776711
LEA29Y (Belatacept) Emory Edmonton Protocol
NCT00468403
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
NCT00734175
H5N1 Priming and Boosting Strategies
NCT00703053
Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects
NCT00565929
Study of Milk Allergy and Tolerance in Children
NCT00778258
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
NCT00723489
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
NCT00742326
Bacterial Vaginosis Home Screening to Prevent STDs
NCT00667368
Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
NCT00709605
Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
NCT00654108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.